Want to see AU:CU6 full AI Analyst Report?

Clarity Pharmaceuticals Ltd. (CU6) Price & Analysis

296 Followers

CU6 Stock Chart & Stats

AU$3.13

-AU$0.24(-5.69%)

At close: Jan 09 4:00 PM EST

AU$3.13

-AU$0.24(-5.69%)

Day’s Range― - ―

52-Week RangeAU$1.80 - AU$5.87

Previous CloseN/A

Volume1.66M

Average Volume (3M)3.27M

Market Cap

AU$824.51M

Enterprise ValueAU$612.94M

Total Cash (Recent Filing)AU$226.25M

Total Debt (Recent Filing)AU$0.00

Price to Earnings (P/E)―

Beta2.58

Next Earnings

Aug 26, 2026

EPS Estimate

-0.15

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.28

Shares Outstanding373,081,240

10 Day Avg. Volume4,406,737

30 Day Avg. Volume3,266,690

Financial Highlights & Ratios

PEG Ratio-0.37

Price to Book (P/B)8.84

Price to Sales (P/S)84.33

P/FCF Ratio-14.52

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

AU$8.41

Price Target Upside168.69% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering1

EPS Forecast (FY)-0.31

Revenue Forecast (FY)AU$1.40M

Bulls Say, Bears Say

Bulls Say

Debt-free Balance SheetA zero-debt capital structure materially lowers financial risk and interest burden for a cash-burning biotech. Over the next 2–6 months this provides flexibility to fund R&D or clinical programs via equity or grants without immediate fixed payments, extending runway and preserving optionality.

Specialized Theranostic PipelineClarity’s focused copper-based theranostic approach targets both imaging and therapy, a structural advantage in precision oncology. A differentiated platform can create higher entry barriers, streamline clinical development pathways, and support integrated commercial offerings over the medium term.

Long-term Revenue Growth TrendDespite a 2025 dip, multi-year revenue expansion demonstrates underlying commercial or grant adoption historically. This persistence suggests market demand or progressing programs that can underpin future commercialization and justify continued investment in R&D and clinical scaling over the next several quarters.

Bears Say

Persistent Cash BurnConsistent negative operating and free cash flow signals ongoing cash consumption from R&D and operations. Over 2–6 months this creates reliance on new financing or partnership deals, risks dilutive capital raises, and constrains discretionary spending and program pacing if fresh capital is delayed.

Widening LossesExpanding operating losses indicate that operating expenses continue to outpace revenues, reducing the firm’s ability to self-fund development. Persistently negative profitability erodes resilience, increases funding needs, and can slow program execution if management must reallocate resources to extend runway.

Declining Equity BaseA materially reduced equity base weakens the balance-sheet buffer to absorb further losses and raises the likelihood of additional capital raises. Over several months this heightens financing risk, could increase dilution for existing shareholders, and limits strategic flexibility for partnerships or M&A.

Clarity Pharmaceuticals Ltd. News

Clarity Pharmaceuticals Issues New Shares Following Option Exercise

The latest announcement is out from Clarity Pharmaceuticals Ltd. ( ($AU:CU6) ). Clarity Pharmaceuticals has issued 110,000 fully...

5d ago

CU6

Clarity Pharmaceuticals Seeks ASX Quotation for Additional 110,000 Shares

Clarity Pharmaceuticals Ltd. ( ($AU:CU6) ) just unveiled an announcement. Clarity Pharmaceuticals Ltd has applied for quotation on...

5d ago

CU6

Clarity’s SAR-bisPSMA data set to showcase prostate cancer advances at EANM 2026

Clarity Pharmaceuticals Ltd. ( ($AU:CU6) ) has shared an update. Clarity Pharmaceuticals will present new data on its...

7d ago

CU6

Clarity Pharmaceuticals marks 100-staff milestone as it builds radiopharmaceutical capabilities

Clarity Pharmaceuticals Ltd. ( ($AU:CU6) ) has provided an announcement. Clarity Pharmaceuticals has reached a 100-employee milestone, reflecting...

11d ago

CU6

Regal Partners exits substantial holding in Clarity Pharmaceuticals

An update from Clarity Pharmaceuticals Ltd. ( ($AU:CU6) ) is now available. Regal Partners Funds Management Pty Ltd...

11d ago

CU6

State Street Group Ceases to Be Substantial Holder in Clarity Pharmaceuticals

Clarity Pharmaceuticals Ltd. ( ($AU:CU6) ) has shared an update. State Street Corporation and several of its asset...

14d ago

CU6

Clarity Pharmaceuticals Issues New Unquoted Options Under Employee Incentive Scheme

Clarity Pharmaceuticals Ltd. ( ($AU:CU6) ) just unveiled an announcement. Clarity Pharmaceuticals has notified the market of the...

1M ago

CU6

Clarity Pharmaceuticals Director Sells Shares to Cover Tax from Option Exercise

Clarity Pharmaceuticals Ltd. ( ($AU:CU6) ) just unveiled an announcement. Clarity Pharmaceuticals has disclosed that Managing Director Michelle...

3M ago

CU6

Clarity Expands U.S. Manufacturing Network for Prostate Cancer Imaging Agent

An announcement from Clarity Pharmaceuticals Ltd. ( ($AU:CU6) ) is now available. Clarity Pharmaceuticals has signed a Commercial...

3M ago

CU6

Citigroup Ceases to Be Substantial Holder in Clarity Pharmaceuticals

An update from Clarity Pharmaceuticals Ltd. ( ($AU:CU6) ) is now available. Citigroup Global Markets Australia Pty Limited...

3M ago

CU6

CU6 FAQ

What was Clarity Pharmaceuticals Ltd.’s price range in the past 12 months?

Clarity Pharmaceuticals Ltd. lowest share price was AU$1.80 and its highest was AU$5.87 in the past 12 months.

What is Clarity Pharmaceuticals Ltd.’s market cap?

Clarity Pharmaceuticals Ltd.’s market cap is AU$824.51M.

When is Clarity Pharmaceuticals Ltd.’s upcoming earnings report date?

Clarity Pharmaceuticals Ltd.’s upcoming earnings report date is Aug 26, 2026 which is in 51 days.

How were Clarity Pharmaceuticals Ltd.’s earnings last quarter?

Clarity Pharmaceuticals Ltd. released its earnings results on Feb 26, 2026. The company reported -AU$0.153 earnings per share for the quarter, missing the consensus estimate of -AU$0.083 by -AU$0.07.

Is Clarity Pharmaceuticals Ltd. overvalued?

According to Wall Street analysts Clarity Pharmaceuticals Ltd.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Clarity Pharmaceuticals Ltd. pay dividends?

Clarity Pharmaceuticals Ltd. does not currently pay dividends.

What is Clarity Pharmaceuticals Ltd.’s EPS estimate?

Clarity Pharmaceuticals Ltd.’s EPS estimate is -0.15.

How many shares outstanding does Clarity Pharmaceuticals Ltd. have?

Clarity Pharmaceuticals Ltd. has 373,081,240 shares outstanding.

What happened to Clarity Pharmaceuticals Ltd.’s price movement after its last earnings report?

Clarity Pharmaceuticals Ltd. reported an EPS of -AU$0.153 in its last earnings report, missing expectations of -AU$0.083. Following the earnings report the stock price went up 0.278%.

Which hedge fund is a major shareholder of Clarity Pharmaceuticals Ltd.?

Currently, no hedge funds are holding shares in AU:CU6

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Clarity Pharmaceuticals Ltd. Stock Smart Score

Neutral

Fundamentals

Return on Equity

-59.59%

Trailing 12-Months

Asset Growth

86.54%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Clarity Pharmaceuticals Ltd.

Clarity Pharmaceuticals Ltd, a clinical stage radiopharmaceutical company, engages in research and development of radiopharmaceuticals products for oncology in Australia and the United States. The company’s lead product is SAR-bisPSMA, a theranostic radiopharmaceutical for the treatment of Prostate Specific Membrane Antigen (PSMA) cancer. It also develops SAR-Bombesin, a pan cancer theranostic radiopharmaceutical to treat prostate, breast, ovarian, urinary, small cell lung cancer, as well as glioblastoma and gastrointestinal stromal tumours; and SARTATE, a theranostic radiopharmaceutical for the treatment of somatostatin receptor 2 (SSTR2) cancer. The company was incorporated in 2010 and is based in Sydney, Australia.

Clarity Pharmaceuticals Ltd. (CU6) Earnings & Revenues

Historic Earnings Reports

CU6 Stock 12 Month Forecast

Average Price Target

AU$8.41

▲(168.69% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"AU$0","9":"AU$9","2.25":"AU$2.25","4.5":"AU$4.5","6.75":"AU$6.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":8.41,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">AU$8.41</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":8.41,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">AU$8.41</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":8.41,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">AU$8.41</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,2.25,4.5,6.75,9],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2025","6":"Dec<br/>2025","9":"Mar<br/>2026","12":"Jun<br/>2026","25":"Jun<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.36,2.8253846153846154,3.290769230769231,3.756153846153846,4.2215384615384615,4.686923076923077,5.1523076923076925,5.617692307692308,6.0830769230769235,6.548461538461538,7.0138461538461545,7.479230769230769,7.9446153846153855,{"y":8.41,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.36,2.8253846153846154,3.290769230769231,3.756153846153846,4.2215384615384615,4.686923076923077,5.1523076923076925,5.617692307692308,6.0830769230769235,6.548461538461538,7.0138461538461545,7.479230769230769,7.9446153846153855,{"y":8.41,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.36,2.8253846153846154,3.290769230769231,3.756153846153846,4.2215384615384615,4.686923076923077,5.1523076923076925,5.617692307692308,6.0830769230769235,6.548461538461538,7.0138461538461545,7.479230769230769,7.9446153846153855,{"y":8.41,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.9,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.7,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.46,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.94,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.75,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.9,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.49,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.71,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.08,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.39,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.32,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.9,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.36,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >